@AdamKinzinger @US_FDA It’s not potential. A lot of companies have ceased selling it. The

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.